Targeting the Fas/FasL signaling pathway in cancer therapy. (Q37975245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Targeting the Fas/FasL signaling pathway in cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

José Fernández-Piqueras

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

12 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

85-101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239437%20AND%20SRC:MED&resulttype=core&format=json

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Metalloproteinase-mediated release of human Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

The role of FasL and Fas in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Molecular ordering of the initial signaling events of CD95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

FLICE is activated by association with the CD95 death-inducing signaling complex (DISC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

CD95's deadly mission in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Defining CD95 as a tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

From cancer immunosurveillance to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Creating immune privilege: active local suppression that benefits friends, but protects foes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

mRNA expression of variant Fas molecules in acute leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Aberrant processing of Fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Mutations in apoptosis genes: a pathogenetic factor for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

An elaborate pathway required for Ras-mediated epigenetic silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Epigenetic changes in tumor Fas levels determine immune escape and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

microRNAs and death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Overcoming drug resistance by enhancing apoptosis of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Lethal effect of the anti-Fas antibody in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Protective effects of HFE7A, mouse anti-human/mouse Fas monoclonal antibody against acute and lethal hepatic injury induced by Jo2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Humanization of the mouse anti-Fas antibody HFE7A and crystal structure of the humanized HFE7A Fab fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Highly frequent anti-idiotype antibody in cynomolgus monkeys developed against mouse-derived regions of anti-Fas antibody humanized by complementarity determining region grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

A Fas agonist induces high levels of apoptosis in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

CD40·FasL and CTLA-4·FasL Fusion Proteins Induce Apoptosis in Malignant Cell Lines by Dual Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Gene transfer of Fas ligand induces tumor regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Fas and mutant estrogen receptor chimeric gene: a novel suicide vector for tamoxifen-inducible apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Spatial and temporal control of transgene expression through ultrasound-mediated induction of the heat shock protein 70B promoter in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Microbial-based therapy of cancer: current progress and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Inhibition of tumor growth using salmonella expressing Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Death receptors: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Novel role of thiadiazolidine derivatives in inducing cell death through Myc-Max, Akt, FKHR, and FasL pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Understanding rituximab function and resistance: implications for tailored therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Clustering of hypermethylated genes in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937

The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.628937